Thrivent Financial for Lutherans Lowers Position in Repligen Corporation $RGEN

Thrivent Financial for Lutherans reduced its stake in Repligen Corporation (NASDAQ:RGEN) by 10.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 411,706 shares of the biotechnology company’s stock after selling 47,114 shares during the quarter. Thrivent Financial for Lutherans owned approximately 0.73% of Repligen worth $67,463,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of RGEN. Measured Wealth Private Client Group LLC purchased a new stake in Repligen in the 3rd quarter valued at $29,000. Bayforest Capital Ltd purchased a new stake in Repligen in the 4th quarter valued at $32,000. Rachor Investment Advisory Services LLC purchased a new stake in Repligen in the 4th quarter valued at $33,000. CWM LLC raised its position in Repligen by 67.2% in the 3rd quarter. CWM LLC now owns 336 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 135 shares during the last quarter. Finally, Farther Finance Advisors LLC boosted its position in Repligen by 61.8% in the fourth quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock worth $55,000 after purchasing an additional 128 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Stock Down 0.5%

RGEN stock opened at $102.87 on Friday. Repligen Corporation has a 1-year low of $100.99 and a 1-year high of $175.77. The company has a current ratio of 9.20, a quick ratio of 7.78 and a debt-to-equity ratio of 0.26. The stock’s fifty day simple moving average is $118.96 and its two-hundred day simple moving average is $142.18. The stock has a market cap of $5.80 billion, a P/E ratio of 114.30, a P/E/G ratio of 1.99 and a beta of 1.09.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 EPS for the quarter, beating analysts’ consensus estimates of $0.38 by $0.10. Repligen had a return on equity of 4.88% and a net margin of 6.73%.The firm had revenue of $194.26 million for the quarter, compared to analysts’ expectations of $192.05 million. During the same quarter in the prior year, the firm earned $0.39 EPS. The business’s revenue for the quarter was up 14.8% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. Analysts expect that Repligen Corporation will post 1.99 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on RGEN. HC Wainwright boosted their price objective on Repligen from $180.00 to $208.00 and gave the stock a “buy” rating in a research report on Monday, March 23rd. Barclays boosted their price objective on Repligen from $145.00 to $160.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. JPMorgan Chase & Co. cut their price objective on Repligen from $180.00 to $165.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 6th. Wall Street Zen cut Repligen from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. Finally, Jefferies Financial Group reissued a “hold” rating and issued a $142.00 price objective on shares of Repligen in a research report on Tuesday, May 5th. Two investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $166.15.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.